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Abstract Eosin-5′-maleimide (EMA) binding test is a flow
cytometric test used to detect hereditary spherocytosis (HS).
To perform the test sample from patients, 5–6 reference sam-
ples of red blood are needed. Our aim was to investigate how
the mean corpuscular volume (MCV) of red blood cells influ-
ences on the value of fluorescence of bounded EMA dye and
how the choice of reference samples affects the test result.
EMA test was performed in peripheral blood from 404 indi-
viduals, including 31 children suffering from HS. Mean fluo-
rescence channel of EMA-RBCs was measured with
Cytomics FC500 flow cytometer. Mean corpuscular volume
of RBCs was assessed with LH750 Beckman Coulter.
Statistical analysis was performed using Graph Pad Prism.
The correlation Spearman coefficient between mean channel
of fluorescence of EMA-RBCs and MCV was r=0.39,
p<0.0001. Interpretation of EMA test depends on MCV of
the reference samples. If reference blood samples have lower
MCV than the patients MCV, EMA test result might be neg-
ative. Due to different MCV values of RBCs in infancy and
ca. Three months later, EMA test in neonates might be
interpreted falsely negative. Samples from children younger
than 3 months old had EMA test result 86.1±11.7 %, whereas
same samples that analyzed 4.1±2.1 later had results of
75.4±4.5 %, p<0.05. Mean fluorescence of EMA-bound
RBC depends on RBC’s volume. MCVof reference samples
affects EMA test results; thus, we recommend selection of
reference samples with MCV in range of ±2 fL compared to
MCVof patient RBC’s.
Keywords Eosin-5′-maleimide . Flowcytometry .Hereditary
spherocytosis . Mean corpuscular volume
Introduction
Hereditary spherocytosis (HS) is an inherited disorder of the
red blood cell plasma membrane. The plasma membrane of
erythrocytes consists of an outer lipid bilayer and an inner
cytoskeleton layer. Subjects with HS are characterized with
inherited deficiency of cytoskeleton proteins: band 3, protein
4.2, α-spectrin, β-spectrin, or/and ankyrin [1–6]. To diagnose
HS, two main laboratory tests are recommended: eosin-5′-
maleimide (EMA) binding assay and cryohemolysis test [3].
Fluorescent EMA dye binds to band-3-protein, and the defi-
ciency of this protein results in decreased fluorescence of the
stain. Mean fluorescence of EMA-bound cells is measured by
flow cytometry [7–15]. In order to interpret the EMA test, 5–6
normal reference samples should be prepared for every sample
from a patient [12]. The exact result of the test is presented as
percentage of decrease of EMA fluorescence compared to
fluorescence of normal RBC bound with EMA. Most pub-
lished studies on EMA test and diagnostics of HS were per-
formed on adult subjects [9, 12]. In such cases, choice of
normal blood samples from blood donors for reference mate-
rials is substantiated. But, the choice of obtaining reference
samples from adult blood donors while testing for pediatric
patients looks controversial. Recommendation of British
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Committee for Standards of Hematology emphasizes
that laboratory diagnostics of HS should be performed
for children older than 6 months old [3]. However, an
EMA binding test is commonly performed on neonates
and infants younger than 6 months, as a first-line test in
HS screening. Considering this, it is imperative that a
suggestion of a suitable reference material should be
made.
This paper examines the correlation between mean channel
of fluorescence of EMA-conjugated RBC and mean corpus-
cular volume (MCV) of studied cells, to show the influence of
reference cell volume on EMA test results in pediatric sam-
ples. It is also aimed to propose the most suitable reference




Results of peripheral blood tests performed for 404 children
from various departments of the pediatric hospital at the
Medical University of Warsaw were taken up for study. The
median age of included subjects was 5 years (1 week to
18 years), both boys and girls. Results of children from on-
cology department were excluded from the study. First group
of studied patients consisted of 373 children without HS.
Second group consisted of 31 children with confirmed
HS. The characterization of the HS subjects is presented
in Table 1. All investigated blood samples were part of
the specimens previously used for requested routine blood
tests—EMA binding test and complete blood count (CBC)
analysis.
A retrospective analysis of EMA test results with regard to
mean corpuscular volume of studied red blood cells was per-
formed for nine children (six girls and three boys), who were
examined in the department twice: 1–3 months after birth and
3–8 months after first analysis.
Both tests were performed using blood collected into tubes
containing EDTA. CBC was analyzed within 2 h after blood
collection. EMA test was performed within 72 h of material
sampling. Blood for EMA test analysis was stored in 4 °C
until testing. Complete blood count result was analyzed with
regard to mean corpuscular volume of red blood cells.
No other hematological parameters were considered. The
study was approved by the Ethics Committee at Medical
University of Warsaw.
Eosin-5-maleimide binding test
The procedure of the test was according to that described
previously [16]. Five microliters of whole blood from each
sample was washed with 0.9 % NaCl solution and incubated
in darkness at room temperature for 1 h with 25 μL of EMA
dye (0.5 mg/mL, in phosphate-buffered saline, PBS; Fluka,
Gillingham, UK), with intermittent mixing. Stained red blood
cells were washed three times using 0.5 %/FBS/PBS and cen-
trifuged after each wash. Cells were suspended in 500 μL of
0.5 % FBS/PBS solution, and 100 μL of labeled cell suspen-
sion was diluted in 1.4 mL of FBS/PBS. Flow cytometric
analysis was carried out using Cytomics FC 500 flow
cytometer (Beckman Coulter, Fullerton, CA, USA). Mean
channel of fluorescence (MCF) units were determined in the
FL-1 channel for 100,000 events.
Table 1 Characteristics of HS patients






1 F 7 months 66,1 - 35,3 +
2 F 9 months 71,2 90 35,8 +
3 F 2 months 79,2 70 34,1 +
4 M 17 years 79,1 50 34,7 +
5 M 3 years 65,9 40 33,3 +
6 M 3 years 72,9 - 36,2 +
7 F 6 years 68,9 - 36,1 +
8 M 9 years 73,9 - 34,7 +
9 M 10 years 77,9 - 34,6 +
10 F 1 month 76,9 240 36,4 +
11 F 4 years 54,2 - 34.0 +
12 M 7 years 82 62 35,8 +
13 M 1 months 77,7 - 33,5 +
14 M 4 years 71,9 45 34,4 +
15 F 4 months 77,1 - 34,3 +
16 M 1 month 71,5 - 34,4 +
17 M 2 months 77,1 - 33,8 +
18 F 2 months 80,5 - 35,8 +
19 F 1 month 67,5 - 34,7 +
20 M 1 month 79,9 - 35,1 +
21 F 5 years 79 - 35,2 +
22 M 13 years 70,7 110 36,6 +
23 M 7 years 69,1 - 35,1 +
24 F 12 years 70 - 36,7 +
25 M 2 years 72,3 - 32,8 +
26 F 4 months 63 85 34,9 +
27 M 6 years 59,4 - 33,5 +
28 F 9 years 58,4 - 35,5 +
29 M 7 years 70,4 - 34,6 +
30 M 8 years 63,2 - 34,6 +
31 M 1 month 77,7 - 36,3 +
EMA result of eosin-5′-maleimide binding test, OF result of osmotic
fragility test determined by an acidified glycerol lysis test (if B-^ the test
was not performed), MCHC mean corpuscular hemoglobin content, B+^
positive family history
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The result of an EMA test is presented as a mean
channel of fluorescence units (MCF) as well as in the
percentage of control fluorescence (%) counted as
follows:
Patient’s % ¼ patient’s MCF
MCF 1þMCF 2þMCF 3þMCF 4þMCF 5þMCF 6ð Þ  6*100%
where:
Patient’s % patient’s result
Patient’s MCF mean channel of fluorescence of stained
RBC of patients
MCF 1–6 mean channel of fluorescence of stained
RBC of control
The cutoff value for positive result of EMA test in the
laboratory is 81 %, as has already been established in a previ-
ous study [17].
We did not base the result of EMA test only on mean
channel of fluorescence, because the results obtained from
different laboratories can vary significantly and are not com-
parable when analyzing the data from the same patient [18].
The flow cytometer was standardized against Flow-set
(Beckman Coulter, USA) fluorospheres.
Statistical analysis
The Spearman’s rank correlation coefficient was used to ana-
lyze correlation between MCV and MCF of EMA. One-way
ANOVA test was used for comparison of MCV and
MCF from three different reference sample groups.
Wilcoxon matched pair test was performed to compare
the difference between EMA test results repeated for
children at different ages. A p value of <0.05 was taken
as being significant for the analysis. Results are present-
ed as mean±standard deviation (SD). Statistical analysis
was performed with GraphPad Prism 6 (GraphPad Software
Inc., USA).
Results
Correlation of MCF and MCV
Correlation between mean corpuscular volume of red blood
cells and mean fluorescence channel of EMA-conjugated
RBC was analyzed for 383 blood samples. Analyzed samples
hadMCV values ranging from 48.8 to 106.2 fL (84.6±7.7 fL),
whereas values of mean fluorescence were 26.7 to 45.0 mean
fluorescence intensity (MFI) units (35.97±3.99 MFI). There
was a positive correlation between both analyzed parameters
with Spearman coefficient 0.39, p<0.0001 (Fig. 1).
Correlation between mean channel of fluorescence andMCV
was also analyzed for 31 blood samples from children suffering
from HS. Average MCF of analyzed samples was 27.7±3.3
MFI; meanwhile, MCV was 82.4±6.8 fL, although no correla-
tion between analyzed parameters was found (p>0.05).
Test interpretation with regard to different MCV values
from reference samples
To obtain the exact result of EMA test, the mean intense of
patient’s dye-conjugated RBC fluorescence should be com-
pared with the average mean fluorescence of EMA-bound
RBC of 5–6 healthy controls. Basing on previous results in-
dicating correlation between EMA fluorescence and MCVof
studied red blood cells, an analysis of interpretation of the test
with regard to different MCV of control samples was per-
formed. For the experiment, 21 control samples were divided
into three groups with different MCVof RBC. The values of
MCV were as follows: 81.6±0.8 fL for MCV1 sample group,
85.4±1.6 fL for MCV2 sample group, and 90.8±1.0 fL for
MCV3 sample group. Mean channel of fluorescence of RBC
for all three sample groups was 34.9±0.8 MFI for MCV1,
37.6±0.8 MFI for MCV2, and 38.9±2.2 MFI for MCV3
(Fig. 2). The differences in the mean corpuscular volume of
RBC for all three MCV sample groups were statistically sig-
nificant, p<0.05 for MCV1 vs MCV2, MCV2 vs MCV3, and
MCV1 vsMCV3. Difference in mean channel of fluorescence
betweenMCV1 andMCV2 as well as MCV1 andMCV3was
statistically significant, p<0.05. There was no significant dif-
ference in MCF between MCV2 and MCV3.
Fig. 1 Correlation between mean corpuscular volume (MCV) of red
blood cell and mean channel of fluorescence (MCF) of EMA-
conjugated erythrocytes, r=0.39, p<0.0001
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In the same experiment, peripheral blood samples from six
patients suffering fromHS were stained with EMA dye. Mean
corpuscular volume and mean channel of fluorescence of pa-
tients’ red blood cells are presented in Table 2 that also pre-
sents exact results of EMA test when different control sample
groups were used as a reference (MCV1,MCV2, andMCV3).
The impact of age on EMA test result
To show how the age of a patient influences the EMA test, a
comparison between results obtained in 9 infants younger than
3months old and results of tests repeated after 4.1±2.1months
was performed. There was a statistically significant difference
between values obtained in infants younger than 3 months
(86.1±11.7 %) and 1–8 months after first analysis (75.4±
4.5 %), p<0.05 (Table 3).
Mean corpuscular volume of analyzed samples was
88.6±6.4 fL (children younger than 3 months) and
77.1±4.0 fL (children aged 4–9 months), respectively,
p<0.05. Additionally, ratios between EMA test result
and MCV (EMA/MCV) for all children were calculated.
Samples collected from children in the first 3 months of their
life were characterized by EMA/MCV ratio of 0.97±0.07,
samples collected from the same children 3.5±2.3 months
after the first test had EMA/MCV ratio of 0.98±0.05. No
difference between obtained values was found.
Discussion
EMA binding test is used as a screening test to diagnose HS
[3, 7–16]. The result of the test is calculated as a decrease in
the fluorescence of EMA-bound red blood cells of patients
compared to EMA fluorescence of six healthy reference
samples.
Most of the laboratories doing EMA testing use adult
blood donors’ samples as reference specimens in every
analysis. However, it is questionable whether this practice is
Fig. 2 Ranges of mean
corpuscular volumes (a) and
corresponding mean channels of
fluorescence (b) for reference
samples used for the
interpretation of EMA test
experiment. Correlation of MCF
and MCV for analyzed samples
(c)
Table 2 Results of MCV, MCF, and EMA test for HS patients with regard to different volume of control red blood cells
Lp MCV MCF Age Reticulocytes
[×106/μl]
EMA result in relation to
MCV1 reference samples [%]
EMA result in relation to
MCV2 reference samples [%]
EMA result in relation to
MCV3 reference samples [%]
1 83.5 28.5 2 m 0.1703 (↑) 81.7 75.8 73.2
2 90.9 30.3 17 y 0.1737 (↑) 86.9 80.6 77.9
3 70.9 25.8 6 y 0.3121 (↑) 74.0 68.6 66.3
4 81.8 26.5 13 y 0.3288 (↑) 76.0 70.5 68.1
5 74.9 25.9 7 y 0.2418 (↑) 74.3 68.9 66.6
6 94.6 28.9 1 m 0.0556 (N) 82.9 76.9 74.3
Results which do not confirm diagnosis of hereditary spherocytosis are bolded
m months, y years, (↑) exceeds reference values for age, (N) within reference values for age
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appropriate with regard to the confirmation of diagnosis in
infants and newborns suspected of HS.
Even though it is recommended that EMA test be done
only in children over 6 months of age [3], most of the blood
samples from infants suspected of HS, with family history of
HS, or in particular with mean corpuscular hemoglobin con-
centration (MCHC) of red blood cells suggesting the disease
[3] are directed for the HS screening test. Based on our expe-
rience, many children suspected of HS in the first days of their
life have a negative result in the EMA test, despite having
typical symptoms of the disease and the results of complete
blood count and biochemical serum analysis being character-
istic for hemolytic anemia. However, the EMA test repeated in
the next 3–6 months confirms the diagnosis. On the other
hand, Christensen et al. suggest that EMA test is the most
reliable test to diagnose HS, with a sensitivity that is compa-
rable to values obtained in adults [19].
Early diagnosis of HS, especially in children with signifi-
cant neonatal jaundice, is necessary to avoid development of
kernicterus [19–21]. Neonates with HS often suffer from se-
vere hyperbilirubinemia and should be treated with prolonged
phototherapy [20]. Anemia requiring repeated transfusions
occurs in the first months of life [3]. A family history of HS
is commonly a factor that allows for the introduction of early
diagnostic procedures in neonates. But, many cases of HS are
de novo mutations, mainly within ankyrin-1 or β-spectrin
genes [20]. The choice of diagnostic methods that can be
successfully used for HS screening in neonates is limited.
Severe hyperbilirubinemia may be associated with other
hemolytic anemias, with the possibility of spherocytes
appearing in blood smear in the course of neonatal im-
mune hemolytic anemia or microangiopathic anemia
[22]. Christensen et al. introduced a BNeonatal HS index^
calculated as MCHC/MCV of studied red blood cells. This
index was shown to have high negative predictive value with
high false positive result number. All studied children had an
index of 0.36 or higher [21]. Last reports show that
cryohemolysis is not useful, not only in the diagnosis of neo-
nates, but even within HS subjects of every age, especially for
distinguishing from other anemias [23]. Finally, EMA binding
test, which is highly specific for HS, could be applied as an
early diagnostic process in neonates; however, together with
complete blood count, result might be unclear [6]. Decreased
fluorescence of EMA-bound red blood cells is found in hered-
itary pyropoikilocytosis, cryohydrocytosis, congenital
dyserythropoietic anemia type II (CDA II), or South-East
Asian ovalocytosis [6].
The problem of low sensitivity of EMA test in newborns
may be associated with the choice of reference samples as a
control for the test. The reference values for mean corpuscular
volume of red blood cells for children aged 0–1 months are
88–125 fL, while reference values for adults are significantly
lower (77–94 fL) [24]. A smaller cell contains less plasma
membrane proteins than a cell with bigger volume; thus, com-
paring RBCs with different volumes may result in false neg-
ative results of EMA test.
Here, we prove that the results of EMA test in newborns
and infants younger than 3 months of age and suspected of HS
are statistically different from the results of the test obtained
from the same patients when they were 4–9 months old. For
3/6 of studied subjects, the result of EMA test performed in the
first examination did not confirm the diagnosis (EMA test
result was higher than 90 %); however, the test repeated after
ca. Three months was indicative for HS. It may be associated
with the volume of studied cells, since MCV in the first anal-
ysis was significantly higher than in the second and the ratio
between EMA test result and MCVof tested blood calculated
for both analysis did not differ from each other. It is an argu-
ment for making a selection of the chosen reference blood
samples where the selected probes should have MCV corre-
sponding to the patient’s RBC MCV.
Results of the performed study show that mean fluores-
cence of EMA dye bound to plasma membrane proteins is
strictly connected with MCV of RBC of analyzed samples.
Table 3 Results of first and
follow-up analysis of EMA test in
children suffering from hereditary
spherocytosis













1 1.5 76.2 88.2 8 71.2 77.9
2 2 73.8 85.2 5 72.6 78.5
3 2 81.4 83.2 3 75.7 76.8
4 1 90.3 90.8 4 77.1 82.1
5 2 90.9 86.6 6 82.1 80.4
6 1 113.2 105 4 83.0 82.4
7 0.5 79.4 86.0 6 71.8 68.9
8 0.5 85.6 71.8 6 71.8 69.6
9 1 84.5 88.1 7 73.0 77.1
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A trend showing the association between volume of cell and
mean fluorescence of EMA-conjugated RBCs was first shown
by King et al. [12]. The correlation between mean channel of
fluorescence and mean cell volume was also demonstrated by
Lijeholm et al. That study was performed for 31 patients suf-
fering from congenital dyserythropoetic anemia type III (CDA
III) [25]. Our results also point to a positive correlation
between the analyzed parameters; however, the correla-
tion coefficient is lower than what the Swedish group has
indicated [25]. The difference may be associated with the dif-
ferent number of studied samples. The correlation between
EMA fluorescence and MCV was also confirmed for healthy
adults (15 studied cases), for hereditary elliptocytosis patients
(22 studied patients), and for subjects with iron deficiency
anemia (IDA) (13 studied patients). No relationship between
MCF andMCVwas found for subjects suffering from HS and
thalassemia minor [10]. Here, we confirm that no correlation
between MCF and MCV was found in patients with HS, pri-
marily because a decreased amount of plasma membrane pro-
teins does not affect the cell volume. The association between
cell size and EMA fluorescence was also observed in a group
of patients suffering from iron deficiency (significantly lower
fluorescence compared to healthy controls) or with macrocy-
tosis (significantly higher fluorescence compared to healthy
donors) [10], which indicates that changes in MCV values are
strictly associated with the intensity of the fluorescence in
EMA test. Increased MCF in macrocytic anemia was also
proved by Kar et al.; however, they do not observe any influ-
ence of lowMCV in microcytic anemia on the fluorescence of
RBCs in EMA test [11]. On the other hand, some cases of IDA
with spectacularly small red blood cells could be false posi-
tively diagnosed as a plasma membrane deficiency in EMA
test, if reference red blood cells have significantly higher
MCV values. In turn, patients with HS suffering also from
anemia caused by folate or vitamin B12 deficiency could be
falsely diagnosed as negative in EMA test, whenMCVof their
RBC would be compared with smaller control red blood cells.
Bolton-Maggs points to the possible masking role of megalo-
blastic anemia with regard to HS [3].
Basing on the proved dependence betweenMCVandMCF,
we decided to study how the test result would be modified if
samples with different MCV were to be chosen as reference
samples in EMA test. Interestingly, if patients suffering from
HS with MCV of RBCs bigger than 83 fL were confronted
with reference samples of MCV in the range of 80–83 fL, the
obtained results of EMA test were negative (>81 %). Test
results were not positive till patients’ samples were compared
with reference RBC with corresponding values of MCV. It
supports our suggestion that during the selection of reference
samples, MCVof the selected specimens should be taken into
account. In the present paper, we point especially to the group
of neonates, sinceMCVof infants undergo significant changes
with age. In most cases of HS in older age,MCVof patients do
not diverge from average MCV for adults. Thus, using refer-
ence blood samples from blood donors is suitable. However,
some HS patients have MCV exceeding the reference range
(mainly by increased number of reticulocytes), and it should
be taken into consideration when analyzing EMA test results.
To conclude, EMA test results strongly depend on fluores-
cence of EMA-bound reference samples used in analysis.
Normally, blood from healthy adult blood donors is used as
a reference. It is only suitable if the test is performed for adult
patients suspected of HS and if their MCV do not exceed
reference values. If the studied sample is obtained from a
child, especially a newborn, a selection of reference samples
with corresponding MCV values should be taken into consid-
eration. Reference samples must be collected from subjects
with no anemia, with normal number of red blood cells and
without any diseases which could affect the complete blood
count result. Based on our observations, we strongly recom-
mend that peripheral blood samples with MCV differing from
the patient’s RBCMCV by ±2 fL should be used as reference.
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